Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
| Status: | Completed |
|---|---|
| Conditions: | Nephrology, Nephrology |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 4/21/2016 |
| Start Date: | April 2006 |
| End Date: | June 2010 |
Cystone for Treatment of Nephrolithiasis
We will investigate the safety and effectiveness of a mixture of 9 east Indian herbs known
as Cystone regarding their ability to dissolve existing kidney stones and prevent formation
of new ones. Cystine and calcium stone formers will be recruited for a 59 week trial. The
first phase of the study will be two 6 weeks periods during which each subject will receive
Cystone or placebo in random order (with a one-week wash out between 6 week treatment
periods). The remaining 46 weeks, each subject will receive Cystone. End points are changes
in urinary chemistries and stone burden by Computerized Tomography (CT) scanning.
as Cystone regarding their ability to dissolve existing kidney stones and prevent formation
of new ones. Cystine and calcium stone formers will be recruited for a 59 week trial. The
first phase of the study will be two 6 weeks periods during which each subject will receive
Cystone or placebo in random order (with a one-week wash out between 6 week treatment
periods). The remaining 46 weeks, each subject will receive Cystone. End points are changes
in urinary chemistries and stone burden by Computerized Tomography (CT) scanning.
Cystone will be used in proven cystine and calcium stone forming adults who are not
pregnant. Subjects must have a measurable stone by CT. The first phase is a double blind,
randomized, placebo controlled cross-over of Cystone and placebo for 6 weeks each separated
by a 1 week washout. Entry, 6 and 12 week 24 hour urine supersaturations or cystine, pH and
sodium determinations will be collected. Then all patients enter an open label phase of 46
weeks, ensuring a 52-week total exposure to Cystone during the 59 week study. Baseline and 1
year stone quantification CT scans will be performed. End points will be changes in urine
chemistry/supersaturation and stone burden. Stone burden was measured by CT, quantitatively
for stone density and volume. All CT images were also reviewed in a blinded fashion by a
radiologist to score each kidney as increased, no change or decreased stone burden.
Statistics and Randomization: Randomization was accomplished using a table provided by the
department of statistics to the study coordinator who was blinded as to whether the patients
received placebo or Cystone®. Biochemical and supersaturation results were analyzed via a
matched pair analysis using the JMP software package (SAS Instituted, Inc.); P values < 0.05
were deemed significant.
pregnant. Subjects must have a measurable stone by CT. The first phase is a double blind,
randomized, placebo controlled cross-over of Cystone and placebo for 6 weeks each separated
by a 1 week washout. Entry, 6 and 12 week 24 hour urine supersaturations or cystine, pH and
sodium determinations will be collected. Then all patients enter an open label phase of 46
weeks, ensuring a 52-week total exposure to Cystone during the 59 week study. Baseline and 1
year stone quantification CT scans will be performed. End points will be changes in urine
chemistry/supersaturation and stone burden. Stone burden was measured by CT, quantitatively
for stone density and volume. All CT images were also reviewed in a blinded fashion by a
radiologist to score each kidney as increased, no change or decreased stone burden.
Statistics and Randomization: Randomization was accomplished using a table provided by the
department of statistics to the study coordinator who was blinded as to whether the patients
received placebo or Cystone®. Biochemical and supersaturation results were analyzed via a
matched pair analysis using the JMP software package (SAS Instituted, Inc.); P values < 0.05
were deemed significant.
Inclusion Criteria:
- Written informed consent In the cystine arm, all patients will have the diagnosis of
cystinuria, made on the basis of a 24-hour urine cystine containing more than 1500
umol of cystine, or a stone compositional analysis of cystine
- Presence of an existing cystine stone in one or both kidneys In the calcium arm, all
patients will have a history of a calcium stone as determined by laboratory analysis.
- Medically effective birth control if fertile female
- Able to comply with protocol
Exclusion Criteria:
- Pregnant
- Subjects under age 18 years
- Obstructing stones
- Urinary Tract Infection that cannot be cleared with single course of antibiotic
- Subjects who decline to provide informed consent
We found this trial at
1
site
Click here to add this to my saved trials
